Suppr超能文献

脂质体药物产品中的辅料相关杂质。

Excipient-related impurities in liposome drug products.

机构信息

Arkansas Laboratory, Office of Regulatory Affairs, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA.

Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, 20993, USA.

出版信息

Int J Pharm. 2024 May 25;657:124164. doi: 10.1016/j.ijpharm.2024.124164. Epub 2024 Apr 28.

Abstract

Liposomes are widely used in the pharmaceutical industry as drug delivery systems to increase the efficacy and reduce the off-target toxicity of active pharmaceutical ingredients (APIs). The liposomes are more complex drug delivery systems than the traditional dosage forms, and phospholipids and cholesterol are the major structural excipients. These two excipients undergo hydrolysis and/or oxidation during liposome preparation and storage, resulting in lipids hydrolyzed products (LHPs) and cholesterol oxidation products (COPs) in the final liposomal formulations. These excipient-related impurities at elevated concentrations may affect liposome stability and exert biological functions. This review focuses on LHPs and COPs, two major categories of excipient-related impurities in the liposomal formulations, and discusses factors affecting their formation, and analytical methods to determine these excipient-related impurities.

摘要

脂质体作为药物传递系统在制药行业中被广泛应用,以提高活性药物成分(APIs)的疗效并降低其脱靶毒性。与传统剂型相比,脂质体是更为复杂的药物传递系统,磷脂和胆固醇是主要的结构性辅料。这两种辅料在脂质体的制备和储存过程中会发生水解和/或氧化,导致最终脂质体配方中存在脂质水解产物(LHPs)和胆固醇氧化产物(COPs)。这些辅料相关杂质在较高浓度下可能会影响脂质体的稳定性并发挥生物学功能。本综述重点讨论了脂质体配方中两种主要的辅料相关杂质,即脂质水解产物(LHPs)和胆固醇氧化产物(COPs),并讨论了影响它们形成的因素以及用于测定这些辅料相关杂质的分析方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验